122 results on '"Pękala E"'
Search Results
2. The anti-inflammatory and antifibrotic effects of a novel, pan-phosphodiesterase inhibitor in murine model of allergic asthma
- Author
-
Wójcik-Pszczoła, K, primary, Pociecha, K, additional, Wyska, E, additional, Chłoń-Rzepa, G, additional, Plutecka, H, additional, Zadrożna, M, additional, Nowak, B, additional, Koczurkiewicz-Adamczyk, P, additional, Pękala, E, additional, and Gosens, R, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Modulation of the TGF-ß-induced epithelial-to-mesenchymal transition by pan-selective PDE inhibitors in A549 cells
- Author
-
Wójcik-Pszczoła, K, primary, Chłoń-Rzepa, G, additional, Jankowska, A, additional, Ślusarczyk, M, additional, Wyska, E, additional, Pociecha, K, additional, Świerczek, A, additional, Koczurkiewicz-Adamczyk, P, additional, Gosens, R, additional, and Pękala, E, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Evaluation of mutagenic and antimutagenic properties of some bioactive xanthone derivatives using Vibrio harveyi test
- Author
-
Słoczyńska, K., Pękala, E., Wajda, A., Węgrzyn, G., and Marona, H.
- Published
- 2010
- Full Text
- View/download PDF
5. Microbial transformation of hydroxy metabolites of 1-oxohexyl derivatives of theobromine by Cunninghamella echinulata NRRL 1384
- Author
-
Pękala, E., Kochan, M., and Carnell, A. J.
- Published
- 2009
6. Cinnamic acid derivatives in cosmetics: current use and future prospects
- Author
-
Gunia-Krzyżak, A., primary, Słoczyńska, K., additional, Popiół, J., additional, Koczurkiewicz, P., additional, Marona, H., additional, and Pękala, E., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Evaluation of mutagenic and antimutagenic properties of some bioactive xanthone derivatives usingVibrio harveyitest
- Author
-
Słoczyńska, K., primary, Pękala, E., additional, Wajda, A., additional, Węgrzyn, G., additional, and Marona, H., additional
- Published
- 2010
- Full Text
- View/download PDF
8. Microbial transformation of hydroxy metabolites of 1-oxohexyl derivatives of theobromine byCunninghamella echinulataNRRL 1384
- Author
-
Pękala, E., primary, Kochan, M., additional, and Carnell, A.J., additional
- Published
- 2009
- Full Text
- View/download PDF
9. Metabolic stability and its role in the discovery of new chemical entities
- Author
-
Słoczyńska Karolina, Gunia-Krzyżak Agnieszka, Koczurkiewicz Paulina, Wójcik-Pszczoła Katarzyna, Żelaszczyk Dorota, Popiół Justyna, and Pękala Elżbieta
- Subjects
metabolic stability ,biotransformation ,intrinsic clearance ,in vitro half-life ,metabolites ,new chemical entity ,Pharmaceutical industry ,HD9665-9675 - Abstract
Determination of metabolic profiles of new chemical entities is a key step in the process of drug discovery, since it influences pharmacokinetic characteristics of therapeutic compounds. One of the main challenges of medicinal chemistry is not only to design compounds demonstrating beneficial activity, but also molecules exhibiting favourable pharmacokinetic parameters. Chemical compounds can be divided into those which are metabolized relatively fast and those which undergo slow biotransformation. Rapid biotransformation reduces exposure to the maternal compound and may lead to the generation of active, non-active or toxic metabolites. In contrast, high metabolic stability may promote interactions between drugs and lead to parent compound toxicity. In the present paper, issues of compound metabolic stability will be discussed, with special emphasis on its significance, in vitro metabolic stability testing, dilemmas regarding in vitro-in vivo extrapolation of the results and some aspects relating to different preclinical species used in in vitro metabolic stability assessment of compounds.
- Published
- 2019
- Full Text
- View/download PDF
10. New developments in A1 and A2 adenosine receptor antagonists
- Author
-
Kieć-Kononowicz, K., primary, Drabczyńska, A., additional, Pękala, E., additional, Michalak, B., additional, Müller, C. E., additional, Schumacher, B., additional, Karolak-Wojciechowska, J., additional, Duddeck, H., additional, Rockitt, S., additional, and Wartchow, R., additional
- Published
- 2001
- Full Text
- View/download PDF
11. Many Labs 5: Testing Pre-Data-Collection Peer Review as an Intervention to Increase Replicability
- Author
-
Lena F. Aeschbach, Balazs Aczel, Maria Vlachou, Blair Saunders, Jennifer A. Joy-Gaba, Ailsa E. Millen, Christopher R. Chartier, Danielle J. Kellier, Carlo Chiorri, Damian Pieńkosz, Tiago Jessé Souza de Lima, Sean Hughes, Carmel A. Levitan, Luca Andrighetto, Mallory C. Kidwell, Domenico Viganola, Sebastiaan Pessers, Sue Kraus, Claudia Chloe Brumbaugh, John E. Edlund, Ernest Baskin, Anna Fedor, Brett Mercier, Michał J. Białek, Sean Coary, Antonia M. Ciunci, Bence E. Bakos, Jon Grahe, Sabina Kołodziej, Radomir Belopavlović, Emilian Pękala, William J. Chopik, Rosanna E. Guadagno, Don A. Moore, Florian Brühlmann, Gideon Nave, Katarzyna Idzikowska, Rachel L. Shubella, Ryan J. Walker, Orsolya Szöke, Mathias Kauff, Ana Orlić, Sara Steegen, Hans IJzerman, Katarzyna Kuchno, Mitchell M. Metzger, Heather M. Claypool, Michael J. Wood, Samuel Lincoln Bezerra Lins, Michael C. Frank, Benjamin Dering, Iris Žeželj, Erica Baranski, Sophia C. Weissgerber, Timothy Razza, Leanne Boucher, Magnus Johannesson, R. Weylin Sternglanz, Yiling Chen, Maya B. Mathur, Christian Nunnally, Jonathan Ravid, Charles R. Ebersole, Lauren Skorb, Kurt Schuepfer, Łukasz Markiewicz, Thomas Schultze, Katherine S. Corker, Thomas Pfeiffer, Darko Stojilović, Oliver Christ, Kayla Ashbaugh, Alan Jern, Caio Ambrosio Lage, Filipe Falcão, Austin Lee Nichols, Peter Babincak, Mauro Giacomantonio, Sean C. Rife, Rafał Muda, Lacy E. Krueger, Jeremy K. Miller, Juliette Richetin, Martin Corley, Venus Meyet, W. Matthew Collins, Luana Elayne Cunha de Souza, Lynda A. R. Stein, Christopher Day, Erica Casini, Astrid Schütz, Ann-Kathrin Torka, Anna Dreber, Diane-Jo Bart-Plange, Steffen R. Giessner, Holly Arrow, Przemysław Sawicki, Joachim Hüffmeier, Ian R. Ferguson, Anna Dalla Rosa, Natasha Tidwell, Hause Lin, Matthew R. Penner, Boban Petrović, Bojana Bodroža, Janos Salamon, Josiah P. J. King, Mark Zrubka, Diane B. V. Bonfiglio, Stefan Schulz-Hardt, Emily Fryberger, Gabriel Baník, David Zealley, Amanda M. Kimbrough, Ewa Hałasa, William Jiménez-Leal, Angelo Panno, Karolina Krasuska, Michael Inzlicht, Jack Arnal, Madhavi Menon, Jia E. Loy, Vanessa S. Kolb, Nicholas G. Bloxsom, Michael H. Bernstein, Máire B. Ford, Grecia Kessinger, Marija V. Čolić, Wolf Vanpaemel, Barnabas Szaszi, Carly tocco, Nick Buttrick, Emanuele Preti, Andres Montealegre, Brian A. Nosek, Katarzyna Gawryluk, Kaylis Hase Rudy, Leigh Ann Vaughn, Anna Palinkas, Rúben Silva, Daniel Wolf, Sarah A. Novak, Aaron L. Wichman, Manuela Thomae, Adam Siegel, Ivana Pedović, Eleanor V. Langford, Kathleen Schmidt, Daniel Storage, Attila Szuts, Ljiljana B. Lazarević, Paul G. Curran, Rias A. Hilliard, Alexander Garinther, Joshua K. Hartshorne, Ani N. Shabazian, Tiago Ramos, Peter Szecsi, Hugh Rabagliati, Kimberly P. Parks, Lily Feinberg, Dylan Manfredi, Ivan Ropovik, Katrin Rentzsch, Michelangelo Vianello, Barbara Sioma, Marton Kovacs, Francis Tuerlinckx, Peter J. B. Hancock, Bradford J. Wiggins, Gavin Brent Sullivan, Danka Purić, Laboratoire Inter-universitaire de Psychologie : Personnalité, Cognition, Changement Social (LIP-PC2S), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Department of Organisation and Personnel Management, Human Resource Excellence, Ebersole, C, Mathur, M, Baranski, E, Bart-Plange, D, Buttrick, N, Chartier, C, Corker, K, Corley, M, Hartshorne, J, Ijzerman, H, Lazarević, L, Rabagliati, H, Ropovik, I, Aczel, B, Aeschbach, L, Andrighetto, L, Arnal, J, Arrow, H, Babincak, P, Bakos, B, Baník, G, Baskin, E, Belopavlović, R, Bernstein, M, Białek, M, Bloxsom, N, Bodroža, B, Bonfiglio, D, Boucher, L, Brühlmann, F, Brumbaugh, C, Casini, E, Chen, Y, Chiorri, C, Chopik, W, Christ, O, Ciunci, A, Claypool, H, Coary, S, Čolić, M, Collins, W, Curran, P, Day, C, Dering, B, Dreber, A, Edlund, J, Falcão, F, Fedor, A, Feinberg, L, Ferguson, I, Ford, M, Frank, M, Fryberger, E, Garinther, A, Gawryluk, K, Ashbaugh, K, Giacomantonio, M, Giessner, S, Grahe, J, Guadagno, R, Hałasa, E, Hancock, P, Hilliard, R, Hüffmeier, J, Hughes, S, Idzikowska, K, Inzlicht, M, Jern, A, Jiménez-Leal, W, Johannesson, M, Joy-Gaba, J, Kauff, M, Kellier, D, Kessinger, G, Kidwell, M, Kimbrough, A, King, J, Kolb, V, Kołodziej, S, Kovacs, M, Krasuska, K, Kraus, S, Krueger, L, Kuchno, K, Lage, C, Langford, E, Levitan, C, de Lima, T, Lin, H, Lins, S, Loy, J, Manfredi, D, Markiewicz, Ł, Menon, M, Mercier, B, Metzger, M, Meyet, V, Millen, A, Miller, J, Montealegre, A, Moore, D, Muda, R, Nave, G, Nichols, A, Novak, S, Nunnally, C, Orlić, A, Palinkas, A, Panno, A, Parks, K, Pedović, I, Pękala, E, Penner, M, Pessers, S, Petrović, B, Pfeiffer, T, Pieńkosz, D, Preti, E, Purić, D, Ramos, T, Ravid, J, Razza, T, Rentzsch, K, Richetin, J, Rife, S, Rosa, A, Rudy, K, Salamon, J, Saunders, B, Sawicki, P, Schmidt, K, Schuepfer, K, Schultze, T, Schulz-Hardt, S, Schütz, A, Shabazian, A, Shubella, R, Siegel, A, Silva, R, Sioma, B, Skorb, L, de Souza, L, Steegen, S, Stein, L, Sternglanz, R, Stojilović, D, Storage, D, Sullivan, G, Szaszi, B, Szecsi, P, Szöke, O, Szuts, A, Thomae, M, Tidwell, N, Tocco, C, Torka, A, Tuerlinckx, F, Vanpaemel, W, Vaughn, L, Vianello, M, Viganola, D, Vlachou, M, Walker, R, Weissgerber, S, Wichman, A, Wiggins, B, Wolf, D, Wood, M, Zealley, D, Žeželj, I, Zrubka, M, Nosek, B, and Faculdade de Psicologia e de Ciências da Educação
- Subjects
replication ,metascience ,Registered Reports ,biology ,media_common.quotation_subject ,Curran ,05 social sciences ,[SHS.PSY]Humanities and Social Sciences/Psychology ,open data ,Art history ,050109 social psychology ,Art ,biology.organism_classification ,preregistered ,050105 experimental psychology ,Attila ,[STAT.ML]Statistics [stat]/Machine Learning [stat.ML] ,0501 psychology and cognitive sciences ,reproducibility ,[STAT.ME]Statistics [stat]/Methodology [stat.ME] ,General Psychology ,media_common - Abstract
Additional co-authors: Ivan Ropovik, Balazs Aczel, Lena F. Aeschbach, Luca Andrighetto, Jack D. Arnal, Holly Arrow, Peter Babincak, Bence E. Bakos, Gabriel Banik, Ernest Baskin, Radomir Belopavlovic, Michael H. Bernstein, Michal Bialek, Nicholas G. Bloxsom, Bojana Bodroža, Diane B. V. Bonfiglio, Leanne Boucher, Florian Bruhlmann, Claudia C. Brumbaugh, Erica Casini, Yiling Chen, Carlo Chiorri, William J. Chopik, Oliver Christ, Antonia M. Ciunci, Heather M. Claypool, Sean Coary, Marija V. Cˇolic, W. Matthew Collins, Paul G. Curran, Chris R. Day, Anna Dreber, John E. Edlund, Filipe Falcao, Anna Fedor, Lily Feinberg, Ian R. Ferguson, Maire Ford, Michael C. Frank, Emily Fryberger, Alexander Garinther, Katarzyna Gawryluk, Kayla Ashbaugh, Mauro Giacomantonio, Steffen R. Giessner, Jon E. Grahe, Rosanna E. Guadagno, Ewa Halasa, Rias A. Hilliard, Joachim Huffmeier, Sean Hughes, Katarzyna Idzikowska, Michael Inzlicht, Alan Jern, William Jimenez-Leal, Magnus Johannesson, Jennifer A. Joy-Gaba, Mathias Kauff, Danielle J. Kellier, Grecia Kessinger, Mallory C. Kidwell, Amanda M. Kimbrough, Josiah P. J. King, Vanessa S. Kolb, Sabina Kolodziej, Marton Kovacs, Karolina Krasuska, Sue Kraus, Lacy E. Krueger, Katarzyna Kuchno, Caio Ambrosio Lage, Eleanor V. Langford, Carmel A. Levitan, Tiago Jesse Souza de Lima, Hause Lin, Samuel Lins, Jia E. Loy, Dylan Manfredi, Łukasz Markiewicz, Madhavi Menon, Brett Mercier, Mitchell Metzger, Venus Meyet, Jeremy K. Miller, Andres Montealegre, Don A. Moore, Rafal Muda, Gideon Nave, Austin Lee Nichols, Sarah A. Novak, Christian Nunnally, Ana Orlic, Anna Palinkas, Angelo Panno, Kimberly P. Parks, Ivana Pedovic, Emilian Pekala, Matthew R. Penner, Sebastiaan Pessers, Boban Petrovic, Thomas Pfeiffer, Damian Pienkosz, Emanuele Preti, Danka Puric, Tiago Ramos, Jonathan Ravid, Timothy S. Razza, Katrin Rentzsch, Juliette Richetin, Sean C. Rife, Anna Dalla Rosa, Kaylis Hase Rudy, Janos Salamon, Blair Saunders, Przemyslaw Sawicki, Kathleen Schmidt, Kurt Schuepfer, Thomas Schultze, Stefan Schulz-Hardt, Astrid Schutz, Ani N. Shabazian, Rachel L. Shubella, Adam Siegel, Ruben Silva, Barbara Sioma, Lauren Skorb, Luana Elayne Cunha de Souza, Sara Steegen, L. A. R. Stein, R. Weylin Sternglanz, Darko Stojilovic, Daniel Storage, Gavin Brent Sullivan, Barnabas Szaszi, Peter Szecsi, Orsolya Szoke, Attila Szuts, Manuela Thomae, Natasha D. Tidwell, Carly Tocco, Ann-Kathrin Torka, Francis Tuerlinckx, Wolf Vanpaemel, Leigh Ann Vaughn, Michelangelo Vianello, Domenico Viganola, Maria Vlachou, Ryan J. Walker, Sophia C. Weissgerber, Aaron L. Wichman, Bradford J. Wiggins, Daniel Wolf, Michael J. Wood, David Zealley, Iris Žeželj, Mark Zrubka, and Brian A. Nosek
- Published
- 2020
12. 5-HT 6 receptor neutral antagonists protect astrocytes: A lesson from 2-phenylpyrrole derivatives.
- Author
-
Drop M, Koczurkiewicz-Adamczyk P, Bento O, Pietruś W, Satała G, Blicharz-Futera K, Canale V, Grychowska K, Bantreil X, Pękala E, Kurczab R, Bojarski AJ, Chaumont-Dubel S, Marin P, Lamaty F, and Zajdel P
- Subjects
- Humans, Structure-Activity Relationship, Molecular Structure, Serotonin Antagonists pharmacology, Serotonin Antagonists chemistry, Serotonin Antagonists chemical synthesis, Molecular Dynamics Simulation, Dose-Response Relationship, Drug, Signal Transduction drug effects, Animals, Astrocytes drug effects, Astrocytes metabolism, Pyrroles pharmacology, Pyrroles chemistry, Pyrroles chemical synthesis, Receptors, Serotonin metabolism
- Abstract
The serotonin type 6 receptor (5-HT
6 R) displays a strong constitutive activity, suggesting it participates largely in the physiological and pathological processes controlled by the receptor. The active states of 5-HT6 R engage particular signal transduction pathways that lead to different biological responses. In this study, we present the development of 5-HT6 R neutral antagonists at Gs signaling built upon the 2-phenylpyrrole scaffold. Using molecular dynamics simulations, we outline the relationship between the exposure of the basic center of the molecules and their ability to target the agonist-activated state of the receptor. Our study identifies compound 30 as a potent and selective neutral antagonist at 5-HT6 R-operated Gs signaling. Furthermore, we demonstrate the cytoprotective effects of 30 and structurally diverse 5-HT6 R neutral antagonists at Gs signaling in C8-D1A cells and human astrocytes exposed to rotenone. This effect is not observed for 5-HT6 R agonists or inverse agonists. In light of these findings, we propose compound 30 as a valuable molecular probe to study the biological effects associated with the agonist-activated state of 5-HT6 R and provide insight into the glioprotective properties of 5-HT6 R neutral antagonists at Gs signaling., Competing Interests: Declaration of competing interest All authors disclose no financial or personal relationships that may be perceived as influencing their work., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
13. Discovery of (E)-3-(4-chlorophenyl)-N-(5-hydroxypentyl)acrylamide among N-substituted cinnamamide derivatives as a novel cosmetic ingredient for hyperpigmentation.
- Author
-
Gunia-Krzyżak A, Popiół J, Słoczyńska K, Żelaszczyk D, Koczurkiewicz-Adamczyk P, Wójcik-Pszczoła K, Bucki A, Sapa M, Kasza P, Borczuch-Kostańska M, Marona H, and Pękala E
- Subjects
- Humans, Animals, Mice, Structure-Activity Relationship, Molecular Structure, Dose-Response Relationship, Drug, Acrylamide chemistry, Acrylamide pharmacology, Drug Discovery, Enzyme Inhibitors pharmacology, Enzyme Inhibitors chemistry, Enzyme Inhibitors chemical synthesis, Agaricales, Hyperpigmentation drug therapy, Monophenol Monooxygenase antagonists & inhibitors, Monophenol Monooxygenase metabolism, Cinnamates chemistry, Cinnamates pharmacology, Cinnamates chemical synthesis, Cosmetics chemistry, Cosmetics pharmacology, Melanins metabolism
- Abstract
Hyperpigmentation disorders may result from inappropriate melanin deposition and/or excessive melanin synthesis. They are classified mainly as aesthetic problems, but they can significantly affect human health by decreasing self-esteem. There are available only limited treatment options for hyperpigmentation disorder, among others, cosmetic products applied topically. Depigmenting ingredients were found to be ineffective and characterized by various side effects. As a result, many efforts are made to discover novel, potent, and safe melanogenesis inhibitors for possible use in topical cosmetic depigmenting formulations. Cinnamic acid derivatives constitute a widely tested group for that purpose. This article reports research in the group of N-alkyl cinnamamide derivatives (un)substituted in phenyl ring. Among tested series, (E)-3-(4-chlorophenyl)-N-(5-hydroxypentyl)acrylamide (compound 21) showed the most promising inhibitory properties in mushroom tyrosinase assay (IC
50 = 36.98 ± 1.07 µM for monophenolase activity, IC50 = 146.71 ± 16.82 µM for diphenolase activity) and melanin production inhibition in B16F10 mouse melanoma cell line at concentration 6.25 µM resulting probably from decreasing of Tyr, Mitf, Tyrp-1, and Tyrp-2 genes expression. This compound also showed melanin production inhibitory properties in pigmented reconstructed human epidermis when used in 1 % and 2 % solutions in 50 % PEG400. In vitro evaluation of its safety profile showed no cytotoxicity to human keratinocytes HaCaT, human skin fibroblasts BJ, and human primary epidermal melanocytes HEMa, no mutagenicity in the Ames test, no genotoxicity in micronucleus test, no phototoxicity, as well as no skin irritation potential tested in PEG400 solution. This compound was also shown to penetrate across the epidermis to reach the possible site of action. The performed research led to classify (E)-3-(4-chlorophenyl)-N-(5-hydroxypentyl)acrylamide as a novel potential depigmenting cosmetic ingredient., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
14. Antibacterial and antibiofilm agents in the group of xanthone derivatives with piperazine moiety active against drug-resistant Helicobacter pylori strains.
- Author
-
Żelaszczyk D, Chmiel A, Gunia-Krzyżak A, Marona H, Krzyżek P, Dworak K, Skiba-Kurek I, Karczewska E, Popiół J, Pękala E, Żmudzki P, Ziąbka M, and Klesiewicz K
- Abstract
Helicobacter pylori (H. pylori) cause chronic inflammation of the gastric mucosa which can lead to epithelial atrophy and metaplasia resulting in peptic ulcer disease and gastric cancer. The increasing resistance of H. pylori to antibiotics and chemotherapeutics used to treat the infection is a serious problem. However, it has been confirmed that the introduction of effective anti-H. pylori therapy can prevent the progression to cancerous changes. This problem calls for the search for new and effective therapies. Xanthones are a group of compounds with extensive biological activities, including antibacterial activity, also against H. pylori. Addressing this issue, the aim of the study was to evaluate the potential of a group of 13 xanthone derivatives against susceptible and resistant H. pylori strains. Moreover, our objective was to conduct tests aimed at determining their ability to inhibit biofilm formation. The antimicrobial evaluation revealed that benzylpiperazine coupled at the C-2 position to xanthone (compounds C11 and C12) had good selective bacteriostatic activity against reference and clinical H. pylori strains (MBC/MIC ratio >4) but with no activity against other bacteria such as Staphylococcus aureus, Escherichia coli, and Lactobacillus paracasei. Analysis of the activity of compounds C11 and C12 against the biofilm formed by H. pylori strain ATCC 700684, and the clinical strain showed that these compounds caused a significant reduction in the amount of biofilm produced (5-20×). Moreover, cell viability analysis confirmed a 3-4× reduction in the viability of cells forming biofilm after treatment with C11 and C12. Finally,both compounds did not impair human fibroblast viability at tested concentrations and were not mutagenic in the Ames test. Therefore, they could be promising leads as antibacterial candidates for multidrug-resistant strains of H. pylori., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.
- Author
-
Murzyn A, Orzeł J, Obajtek N, Mróz A, Miodowska D, Bojdo P, Gąsiorkiewicz B, Koczurkiewicz-Adamczyk P, Piska K, and Pękala E
- Subjects
- Humans, Animals, Neoplasms drug therapy, Aclarubicin pharmacokinetics, Aclarubicin pharmacology, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacology
- Abstract
Aclarubicin (aclacinomycin A) is one of the anthracycline antineoplastic antibiotics with a multifaceted mechanism of antitumor activity. As a second-generation drug, it offers several advantages compared to standard anthracycline drugs such as doxorubicin or daunorubicin, which could position it as a potential blockbuster drug in antitumor therapy. Key mechanisms of action for aclarubicin include the inhibition of both types of topoisomerases, suppression of tumor invasion processes, generation of reactive oxygen species, inhibition of chymotrypsin-like activity, influence on cisplatin degradation, and inhibition of angiogenesis. Therefore, aclarubicin appears to be an ideal candidate for antitumor therapy. However, despite initial interest in its clinical applications, only a limited number of high-quality trials have been conducted thus far. Aclarubicin has primarily been evaluated as an induction therapy in acute myeloid and lymphoblastic leukemia. Studies have indicated that aclarubicin may hold significant promise for combination therapies with other anticancer drugs, although further research is needed to confirm its potential. This paper provides an in-depth exploration of aclarubicin's diverse mechanisms of action, its pharmacokinetics, potential toxicity, and the clinical trials in which it has been investigated., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. In vitro safety evaluation of (6-methoxy-9-oxo-9 H -xanthen-2-yl)methyl ( E )-3-(2,4-dimethoxyphenyl)acrylate (K-116) - the novel potential UV filter designed by means of a double chromophore strategy.
- Author
-
Popiół J, Gunia-Krzyżak A, Słoczyńska K, Piska K, Kocot N, Żelaszczyk D, Krupa A, Wójcik-Pszczoła K, Marona H, and Pękala E
- Subjects
- Skin drug effects, Skin metabolism, Humans, Mutagenicity Tests, Animals, Ultraviolet Rays, Sunscreening Agents toxicity, Acrylates
- Abstract
The use of topical photoprotection is necessary to reduce adverse effects caused by excessive exposure to ultraviolet radiation. Despite the high standards set for UV filters, many of them may contribute to the occurrence of adverse effects. The newly synthesised compound K-116, the ( E )-cinnamoyl xanthone derivative, could be an alternative. We conducted extended in vitro safety evaluation of compound K-116. The research included assessment of irritation potential on skin tissue, evaluation of penetration through the epidermis, and assessment of phototoxicity, and mutagenicity. Additionally, the eco-safety of compound K-116 was evaluated, including an examination of its degradation pathway in the Cunninghamella echinulata model, as well as in silico simulation of the toxicity of both the parent compound and its degradation products. The research showed that compound K-116 tested in future application conditions is deprived of skin irritant potential additionally it does not penetrate through the epidermis. Results showed that K-116 concentrate is not phototoxic and not mutagenic. The eco-safety studies showed that it undergoes biodegradation in 27% in Cunninghamella echinulata model. The parent compound and formed metabolite are less toxic than reference UV filters (octinoxate and octocrylene).
- Published
- 2024
- Full Text
- View/download PDF
17. Mechanochemical synthesis and anticonvulsant activity of 3-aminopyrrolidine-2,5-dione derivatives.
- Author
-
Jarzyński S, Rapacz A, Dziubina A, Pękala E, Popiół J, Piska K, Wojtulewski S, and Rudolf B
- Subjects
- Humans, Mice, Animals, Spectroscopy, Fourier Transform Infrared, Seizures drug therapy, Seizures prevention & control, Ethosuximide therapeutic use, Pentylenetetrazole, Structure-Activity Relationship, Molecular Structure, Anticonvulsants pharmacology, Anticonvulsants therapeutic use, Anticonvulsants chemistry, Neuroblastoma drug therapy
- Abstract
A series of 3-aminopyrrolidine-2,5-dione derivatives was synthesized and tested for anticonvulsant activity. Succinimide derivatives were obtained from a simple solvent-based reaction and a mechanochemical aza-Michael reaction of maleimide or its N-substituted derivatives with selected amines. The structure of the compounds was confirmed by spectroscopic methods (NMR, FT-IR, HPLC, ESI-MS, EA and XRD for four compounds). The cytotoxic activity of the succinimide derivatives was evaluated using HepG2 cells for hepatocytotoxicity and SH-SY5Y cells for neurocytotoxicity. None of the studied compounds showed hepatocytotoxicity and two showed neurocytotoxicity. Initial anticonvulsant screening was performed in mice using the psychomotor seizure test (6 Hz, 32 mA). The selected compounds were evaluated in the following acute models of epilepsy: the maximal electroshock test, psychomotor seizure test (6 Hz, 44 mA), subcutaneous pentylenetetrazole seizure test, and acute neurotoxicity (rotarod test). The most active compound 3-((4-chlorophenyl)amino)pyrrolidine-2,5-dione revealed antiseizure activity in all seizure models (including pharmacoresistant seizures) and showed better median effective doses (ED
50 ) and protective index values than the reference compound, ethosuximide. Furthermore, 3-(benzylamino)pyrrolidine-2,5-dione and 3-(phenylamino)pyrrolidine-2,5-dione exhibited antiseizure activity in the 6 Hz and MES tests, and 3-(butylamino)-1-phenylpyrrolidine-2,5-dione and 3-(benzylamino)-1-phenylpyrrolidine-2,5-dione exhibited antiseizure activity in the 6 Hz test. All active compounds demonstrated low in vivo neurotoxicity in the rotarod test and yielded favourable protective indices., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
18. Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance.
- Author
-
Piska K, Koczurkiewicz-Adamczyk P, Jamrozik M, Bucki A, Kołaczkowski M, and Pękala E
- Subjects
- Humans, Adenosine Triphosphatases metabolism, ATP Binding Cassette Transporter, Subfamily B metabolism, Cell Line, Tumor, Daunorubicin pharmacology, Doxorubicin pharmacology, Anthracyclines pharmacology, Neoplasms
- Abstract
1. ABCB1 (P-glycoprotein, MDR1) is one of the most important transporter involved in cancer multi-drug resistance. It also plays a significant role in cancer resistance against anthracyclines, an anticancer group of drugs, including doxorubicin and daunorubicin. Several intracellular enzymes metabolise anthracyclines to carbonyl-reduced, hydroxy metabolites, which have impaired cytotoxic properties. However, metabolite efflux by ABCB1 transporter is not well characterised, while it may be the mechanism responsible for the metabolites' lack of activity.2. In this study recombinant ABCB1 ATPase transporter assay; anthracyclines accumulation assay in resistant cells overexpressing ABCB1; and molecular modelling were used to investigate anthracyclines: doxorubicin and daunorubicin and their carbonyl-reduced metabolites (doxorubicinol, daunorubicinol) susceptibility for ABCB1-dependent efflux.3. Based on the kinetics parameters of ATPase activity of ABCB1, it was found that daunorubicinol exerted an exceptionally high potential for being effluxed by the ABCB1 transporter. ABCB1 significantly affected the accumulation pattern of studied chemicals in resistant cancer cells. Doxorubicin and daunorubicinol accumulation were influenced by the activity of ABCB1 modulator - valspodar.4. Results indicate that ABCB1 activity affects not only anthracyclines but also their metabolites. Therefore crosstalk between the process of anthracyclines metabolism and metabolite efflux may be the mechanism of impairing anticancer properties of anthracyclines metabolites.
- Published
- 2023
- Full Text
- View/download PDF
19. In silico and in vitro evaluation of a safety profile of a cosmetic ingredient: 4-methoxychalcone (4-MC).
- Author
-
Gunia-Krzyżak A, Popiół J, Słoczyńska K, Żelaszczyk D, Orzeł K, Koczurkiewicz-Adamczyk P, Wójcik-Pszczoła K, Kasza P, Borczuch-Kostańska M, and Pękala E
- Subjects
- Animals, Antioxidants, Mammals, Chalcones toxicity, Dermatitis, Phototoxic, Cosmetics toxicity
- Abstract
Chalcone is an important scaffold within medicinal and cosmetic chemistry. The structure enables multiple modifications which may result in obtaining compounds with desirable bioactivity. One of the chalcone derivatives, 4-methoxychalcone is a known cosmetic ingredient indexed in Cosing database as an antioxidant, bleaching, and skin conditioning substance. We investigated its in silico and in vitro safety profile. In silico study using Derek Nexus showed its potential of skin sensitisation, equivocal nature of chromosome damage in vitro in mammals, but also no mutagenic properties. In vitro research proved its activity as melanogenesis inhibitor in B16F10 cell line at the doses 12.5-3.125 μM. Evaluations performed in various cell lines showed that the cytotoxic doses were 50-25 μM. Tests in Episkin™ proved its ability to penetrate across epidermis and enabled classification of 2% formulation in PEG as non-irritant. In micronucleus tests it showed no genotoxicity. Studies in Cunninghamella echinulata model proved that 4-methoxychalcone was metabolised to less lipophilic products. 4-methoxychalcone showed phototoxic potential, its EC
50 (+UV) = 3.57 μg/mL, PIF = 10.19 and MPE = 0.428 were comparable to chlorpromazine. Moreover, 4-methoxychalcone showed ecotoxic potential in Microtox® assay with EC50 (5 min) = 0.0047 mg/L and EC50 (15 min) = 0.0033 mg/L. Although active doses were lower than toxic ones, some potential safety risks were noticed. Especially, due to the phototoxicity potential of 4-methoxychalcone, its use as depigmenting agent should involve avoidance of sunlight and use of appropriate photoprotection., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
20. Antidepressant pharmaceuticals in aquatic systems, individual-level ecotoxicological effects: growth, survival and behavior.
- Author
-
Słoczyńska K, Orzeł J, Murzyn A, Popiół J, Gunia-Krzyżak A, Koczurkiewicz-Adamczyk P, and Pękala E
- Subjects
- Reproducibility of Results, Antidepressive Agents toxicity, Pharmaceutical Preparations, Ecotoxicology methods, Water Pollutants, Chemical toxicity
- Abstract
The growing consumption of antidepressant pharmaceuticals has resulted in their widespread occurrence in the environment, particularly in waterways with a typical concentration range from ng L
-1 to μg L-1 . An increasing number of studies have confirmed the ecotoxic potency of antidepressants, not only at high concentrations but also at environmentally relevant levels. The present review covers literature from the last decade on the individual-level ecotoxicological effects of the most commonly used antidepressants, including their impact on behavior, growth, and survival. We focus on the relationship between antidepressants physico-chemical properties and dynamics in the environment. Furthermore, we discuss the advantages of considering behavioral changes as sensitive endpoints in ecotoxicology, as well as some current methodological shortcomings in the field, including low standardization, reproducibility and context-dependency., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier B.V.)- Published
- 2023
- Full Text
- View/download PDF
21. Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma.
- Author
-
Wójcik-Pszczoła K, Pociecha K, Chłoń-Rzepa G, Zadrożna M, Nowak B, Plutecka H, Koczurkiewicz-Adamczyk P, Przejczowska-Pomierny K, Pękala E, Gosens R, and Wyska E
- Subjects
- Female, Mice, Animals, Ovalbumin, Disease Models, Animal, Phosphodiesterase Inhibitors adverse effects, Phosphodiesterase Inhibitors metabolism, Inflammation metabolism, Bronchoalveolar Lavage Fluid, Mice, Inbred BALB C, Airway Remodeling, Lung metabolism, Asthma chemically induced, Asthma drug therapy, Anti-Asthmatic Agents therapeutic use
- Abstract
Asthma is a heterogeneous, chronic respiratory disease characterized by airway inflammation and remodeling. Phosphodiesterase (PDE) inhibitors represent one of the intensively studied groups of potential anti-asthmatic agents due to their affecting both airway inflammation and remodeling. However, the effect of inhaled pan-PDE inhibitors on allergen induced asthma has not been reported to date. In this study we investigated the impact of two, representative strong pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione: compound 38 and 145, on airway inflammation and remodeling in murine model of ovalbumin (OVA)-challenged allergic asthma. Female Balb/c mice were sensitized and challenged with OVA, 38 and 145 were administrated by inhalation, before each OVA challenge. The inhaled pan-PDE inhibitors markedly reduced the OVA-induced airway inflammatory cell infiltration, eosinophil recruitment, Th2 cytokine level in bronchoalveolar lavage fluid, as well as both, total and OVA-specific IgE levels in plasma. In addition, inhaled 38 and 145 decreased many typical features of airway remodeling, including goblet cell metaplasia, mucus hypersecretion, collagen overproduction and deposition, as well as Tgfb1, VEGF, and α-SMA expression in airways of allergen challenged mice. We also demonstrated that both 38 and 145 alleviate airway inflammation and remodelling by inhibition of the TGF-β/Smad signaling pathway activated in OVA-challenged mice. Taken together, these results suggest that the investigated pan-PDE inhibitors administered by inhalation are dual acting agents targeting both airway inflammation and remodeling in OVA-challenged allergic asthma and may represent promising, anti-asthmatic drug candidates., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
22. Synthesis, Antimicrobial and Mutagenic Activity of a New Class of d-Xylopyranosides.
- Author
-
Sikora K, Szweda P, Słoczyńska K, Samaszko-Fiertek J, Madaj J, Liberek B, Pękala E, and Dmochowska B
- Abstract
Eight N -[2-(2',3',4'-tri- O -acetyl-α/β-d-xylopyranosyloxy)ethyl]ammonium bromides, a new class of d-xylopyranosides containing a quaternary ammonium aglycone, were obtained. Their complete structure was confirmed using NMR spectroscopy (
1 H,13 C, COSY and HSQC) and high-resolution mass spectrometry (HRMS). An antimicrobial activity against fungi ( Candida albicans , Candida glabrata ) and bacteria ( Staphylococcus aureus , Escherichia coli ) and a mutagenic Ames test with Salmonella typhimurium TA 98 strain were performed for the obtained compounds. The greatest activity against the tested microorganisms was shown by glycosides with the longest (octyl) hydrocarbon chain in ammonium salt. None of the tested compounds exhibited mutagenic activity in the Ames test.- Published
- 2023
- Full Text
- View/download PDF
23. Design and synthesis of novel arylurea derivatives of aryloxy(1-phenylpropyl) alicyclic diamines with antimicrobial activity against multidrug-resistant Gram-positive bacteria.
- Author
-
Canale V, Czekajewska J, Klesiewicz K, Papież M, Kuziak A, Witek K, Piska K, Niemiec D, Kasza P, Pękala E, Empel J, Tomczak M, Karczewska E, and Zajdel P
- Subjects
- Animals, Horses, Linezolid pharmacology, Vancomycin pharmacology, Staphylococcus aureus, Diamines pharmacology, Gram-Negative Bacteria, Gram-Positive Bacteria, Bacteria, Microbial Sensitivity Tests, Mammals, Anti-Bacterial Agents pharmacology, Anti-Infective Agents pharmacology
- Abstract
The alarming increase in the resistance of bacteria to the currently available antibiotics necessitates the development of new effective antimicrobial agents that are active against bacterial pathogens causing major public health problems. For this purpose, our in-house libraries were screened against a wide panel of clinically relevant Gram-positive and Gram-negative bacteria, based on which compound I was selected for further optimization. Synthetic efforts in a group of arylurea derivatives of aryloxy(1-phenylpropyl) alicyclic diamines, followed with an in vitro evaluation of the activity against multidrug-resistant strains identified compound 44 (1-(3-chlorophenyl)-3-(1-{3-phenyl-3-[3-(trifluoromethyl)phenoxy] propyl}piperidin-4-yl)urea). Compound 44 showed antibacterial activity against Gram-positive bacteria including fatal drug-resistant strains i.e., Staphylococcus aureus (methicillin-resistant, MRSA; vancomycin-intermediate, VISA) and Enterococcus faecium (vancomycin-resistant, VREfm) at low concentrations (0.78-3.125 μg/mL) comparable to last resort antibiotics (i.e., vancomycin and linezolid). It is also potent against biofilm-forming S. aureus and Staphylococcus epidermidis (including linezolid-resistant, LRSE) strains, but with no activity against Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa). Compound 44 showed strong bactericidal properties against susceptible and drug-resistant Gram-positive bacteria. Depolarization of the bacterial cytoplasmic membrane induced by compound 44 suggests a dissipation of the bacterial membrane potential as its mechanism of antibacterial action. The high antimicrobial activity of compound 44, along with its selectivity over mammalian cells (lung MCR-5 and skin BJ fibroblast cell lines) and no hemolytic properties toward horse erythrocytes, proposes arylurea derivatives of aryloxy(1-phenylpropyl) alicyclic diamines for development of novel antibacterial agents., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Masson SAS.)
- Published
- 2023
- Full Text
- View/download PDF
24. Saponin Fraction CIL1 from Lysimachia ciliata L. Enhances the Effect of a Targeted Toxin on Cancer Cells.
- Author
-
Koczurkiewicz-Adamczyk P, Grabowska K, Karnas E, Piska K, Wnuk D, Klaś K, Galanty A, Wójcik-Pszczoła K, Michalik M, Pękala E, Fuchs H, and Podolak I
- Abstract
Saponins are plant metabolites that possess multidirectional biological activities, among these is antitumor potential. The mechanisms of anticancer activity of saponins are very complex and depend on various factors, including the chemical structure of saponins and the type of cell they target. The ability of saponins to enhance the efficacy of various chemotherapeutics has opened new perspectives for using them in combined anticancer chemotherapy. Co-administration of saponins with targeted toxins makes it possible to reduce the dose of the toxin and thus limit the side effects of overall therapy by mediating endosomal escape. Our study indicates that the saponin fraction CIL1 of Lysimachia ciliata L. can improve the efficacy of the EGFR-targeted toxin dianthin (DE). We investigated the effect of cotreatment with CIL1 + DE on cell viability in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, on proliferation in a crystal violet assay (CV) and on pro-apoptotic activity using Annexin V/7 Actinomycin D (7-AAD) staining and luminescence detection of caspase levels. Cotreatment with CIL1 + DE enhanced the target cell-specific cytotoxicity, as well as the antiproliferative and proapoptotic properties. We found a 2200-fold increase in both the cytotoxic and antiproliferative efficacy of CIL1 + DE against HER14-targeted cells, while the effect on control NIH3T3 off-target cells was less profound (6.9- or 5.4-fold, respectively). Furthermore, we demonstrated that the CIL1 saponin fraction has a satisfactory in vitro safety profile with a lack of cytotoxic and mutagenic potential.
- Published
- 2023
- Full Text
- View/download PDF
25. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
- Author
-
Jamrozik M, Piska K, Bucki A, Koczurkiewicz-Adamczyk P, Sapa M, Władyka B, Pękala E, and Kołaczkowski M
- Subjects
- Humans, Rats, Animals, Molecular Docking Simulation, Cardiotoxicity, Anthracyclines pharmacology, Anthracyclines metabolism, Antibiotics, Antineoplastic pharmacology, Daunorubicin pharmacology, Anti-Bacterial Agents, Carbonyl Reductase (NADPH), Antineoplastic Agents pharmacology
- Abstract
Anthracycline antibiotics (ANT) are among the most widely used anticancer drugs. Unfortunately, their use is limited due to the development of drug resistance and cardiotoxicity. ANT metabolism, performed mainly by two enzymes-aldo-keto reductase 1C3 (AKR1C3) and carbonyl reductase 1 (CBR1)-is one of the proposed mechanisms generated by the described effects. In this study, we evaluated the CBR1 inhibitory properties of ASP9521, a compound already known as potent AKR1C3 inhibitor. First, we assessed the possibility of ASP9521 binding to the CBR1 catalytic site using molecular docking and molecular dynamics. The research revealed a potential binding mode of ASP9521. Moderate inhibitory activity against CBR1 was observed in studies with recombinant enzymes. Finally, we examined whether ASP9521 can improve the cytotoxic activity of daunorubicin against human lung carcinoma cell line A549 and assessed the cardioprotective properties of ASP9521 in a rat cardiomyocytes model (H9c2) against doxorubicin- and daunorubicin-induced toxicity. The addition of ASP9521 ameliorated the cytotoxic activity of daunorubicin and protected rat cardiomyocytes from the cytotoxic effect of both applied drugs. Considering the favorable bioavailability and safety profile of ASP9521, the obtained results encourage further research. Inhibition of both AKR1C3 and CBR1 may be a promising method of overcoming ANT resistance and cardiotoxicity.
- Published
- 2023
- Full Text
- View/download PDF
26. KM-408, a novel phenoxyalkyl derivative as a potential anticonvulsant and analgesic compound for the treatment of neuropathic pain.
- Author
-
Waszkielewicz A, Marona H, Pańczyk-Straszak K, Filipek B, Rapacz A, Sałat K, Kubacka M, Cios A, Fedak F, Walczak M, Hubicka U, Kwiecień A, Żuromska-Witek B, Szafrański PW, Koczurkiewicz-Adamczyk P, Pękala E, Przejczowska-Pomierny K, Pociecha K, and Wyska E
- Subjects
- Rats, Mice, Animals, Guinea Pigs, Anticonvulsants pharmacology, Anticonvulsants therapeutic use, Analgesics pharmacology, Analgesics therapeutic use, Capsaicin, Disease Models, Animal, Neuralgia drug therapy, Epilepsy drug therapy
- Abstract
Background: Epilepsy frequently coexists with neuropathic pain. Our approach is based on the search for active compounds with multitarget profiles beneficial in terms of potential side effects and on the implementation of screening for potential multidirectional central activity., Methods: Compounds were synthesized by means of chemical synthesis. After antiseizure and neurotoxicity screening in vivo, KM-408 and its enantiomers were chosen for analgesic activity evaluations. Further safety studies included acute toxicity in mice, the effect on normal electrocardiogram and on blood pressure in rats, whole body plethysmography in rats, and in vitro and biochemical assays. Pharmacokinetics has been studied in rats after iv and po administration. Metabolism has been studied in vivo in rat serum and urine. Radioligand binding studies were performed as part of the mechanism of action investigation., Results: Selected results for KM-408: K
i sigma = 7.2*10-8 ; Ki 5-HT1A = 8.0*10-7 ; ED50 MES (mice, ip) = 13.3 mg/kg; formalin test (I phase, mice, ip)-active at 30 mg/kg; SNL (rats, ip)-active at 6 mg/kg; STZ-induced pain (mice, ip)-active at 1 mg/kg (von Frey) and 10 mg/kg (hot plate); hot plate test (mice, ip)-active at 30 mg/kg; ED50 capsaicin test (mice, ip) = 18.99 mg/kg; tail immersion test (mice)-active at 0.5%; corneal anesthesia (guinea pigs)-active at 0.125%; infiltration anesthesia (guinea pigs)-active at 0.125%., Conclusions: Within the presented study a novel compound, R,S-2-((2-(2-chloro-6-methylphenoxy)ethyl)amino)butan-1-ol hydrochloride (KM-408) with dual antiseizure and analgesic activity has been developed for potential use in neuropathic pain treatment., (© 2022. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
27. 1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT 6 R Antagonists: Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity.
- Author
-
Canale V, Trybała W, Chaumont-Dubel S, Koczurkiewicz-Adamczyk P, Satała G, Bento O, Blicharz-Futera K, Bantreil X, Pękala E, Bojarski AJ, Lamaty F, Marin P, and Zajdel P
- Subjects
- Ligands, Cognition, Piperazines pharmacology, Serotonin pharmacology, Drug Inverse Agonism
- Abstract
In addition to the canonical Gs adenylyl cyclase pathway, the serotonin type 6 receptor (5-HT
6 R) recruits additional signaling pathways that control cognitive function, brain development, and synaptic plasticity in an agonist-dependent and independent manner. Considering that aberrant constitutive and agonist-induced active states are involved in various pathological mechanisms, the development of biased ligands with different functional profiles at specific 5-HT6 R-elicited signaling pathways may provide a novel therapeutic perspective in the field of neurodegenerative and psychiatric diseases. Based on the structure of SB-258585, an inverse agonist at 5-HT6 R-operated Gs and Cdk5 signaling, we designed a series of 1-(arylsulfonyl-isoindol-2-yl)piperazine derivatives and synthesized them using a sustainable mechanochemical method. We identified the safe and metabolically stable biased ligand 3g , which behaves as a neutral antagonist at the 5-HT6 R-operated Gs signaling and displays inverse agonist activity at the Cdk5 pathway. Inversion of the sulfonamide bond combined with its incorporation into the isoindoline scaffold switched the functional profile of 3g at Gs signaling with no impact at the Cdk5 pathway. Compound 3g reduced the cytotoxicity of 6-OHDA and produced a glioprotective effect against rotenone-induced toxicity in C8-D1A astrocyte cell cultures. In view of these findings, compound 3g can be considered a promising biased ligand to investigate the role of the 5-HT6 R-elicited Gs and Cdk5 signaling pathways in neurodegenerative diseases.- Published
- 2022
- Full Text
- View/download PDF
28. In silico and in vitro ADME-Tox analysis and in vivo pharmacokinetic study of representative pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione.
- Author
-
Wójcik-Pszczoła K, Szafarz M, Pociecha K, Słoczyńska K, Piska K, Koczurkiewicz-Adamczyk P, Kocot N, Chłoń-Rzepa G, Pękala E, and Wyska E
- Abstract
Phosphodiesterase (PDE) inhibitors represent a wide class of chemically different compounds that have been extensively studied in recent years. Their anti-inflammatory and anti-fibrotic effects are particularly desirable in the treatment of chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). Due to diversified expression of individual PDEs within cells and/or tissues as well as PDE signaling compartmentalization, pan-PDE inhibitors (compounds capable of simultaneously blocking various PDE subtypes) are of particular interest. Recently, a large group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione (theophylline) was designed and synthesized. These compounds were characterized as potent pan-PDE inhibitors and their prominent anti-inflammatory and anti-fibrotic activity in vitro has been proved. Herein, we investigated a general in vitro safety profile and pharmacokinetic characteristics of two leading compounds from this group: a representative compound with N'-benzylidenebutanehydrazide moiety (38) and a representative derivative containing N-phenylbutanamide fragment (145). Both tested pan-PDE inhibitors revealed no cytotoxic, mutagenic, and genotoxic activity in vitro, showed moderate metabolic stability in mouse and human liver microsomes, as well as fell into the low or medium permeation category. Additionally, 38 and 145 revealed a lack of interaction with adenosine receptors, including A
1 , A2A , and A2B . Pharmacokinetic analysis revealed that both tested 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione were effectively absorbed from the peritoneal cavity. Simultaneously, they were extensively distributed to mouse lungs and after intraperitoneal (i.p.) administration were detected in bronchoalveolar lavage fluid. These findings provide evidence that investigated compounds represent a new drug candidates with a favorable in vitro safety profile and satisfactory pharmacokinetic properties after a single i.p. administration. As the next step, further pharmacokinetic studies after multiple i.p. and p.o. doses will be conducted to ensure effective 38 and 145 serum and lung concentrations for a longer period of time. In summary, 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione represent a promising compounds worth testing in animal models of chronic respiratory diseases, the etiology of which involves various PDE subtypes., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
29. Novel Antibacterial, Cytotoxic and Catalytic Activities of Silver Nanoparticles Synthesized from Acidophilic Actinobacterial SL19 with Evidence for Protein as Coating Biomolecule.
- Author
-
Wypij M, Ostrowski M, Piska K, Wójcik-Pszczoła K, Pękala E, Rai M, and Golińska P
- Subjects
- Ampicillin, Anti-Bacterial Agents chemistry, Escherichia coli metabolism, Humans, Kanamycin, Microbial Sensitivity Tests, Porins, Silver chemistry, Soil, Streptomycin, Tetracyclines, Anti-Infective Agents metabolism, Antineoplastic Agents chemistry, Metal Nanoparticles chemistry
- Abstract
Silver nanoparticles (AgNPs) have potential applications in medicine, photocatalysis, agriculture, and cosmetic fields due to their unique physicochemical properties and strong antimicrobial activity. Here, AgNPs were synthesized using actinobacterial SL19 strain, isolated from acidic forest soil in Poland, and confirmed by UV-vis and FTIR spectroscopy, TEM, and zeta potential analysis. The AgNPs were polydispersed, stable, spherical, and small, with an average size of 23 nm. The FTIR study revealed the presence of bonds characteristic of proteins that cover nanoparticles. These proteins were then studied by using liquid chromatography with tandem mass spectrometry (LC-MS/ MS) and identified with the highest similarity to hypothetical protein and porin with molecular masses equal to 41 and 38 kDa, respectively. Our AgNPs exhibited remarkable antibacterial activity against Escherichia coli and Pseudomonas aeruginosa . The combined, synergistic action of these synthesized AgNPs with commercial antibiotics (ampicillin, kanamycin, streptomycin, and tetracycline) enabled dose reductions in both components and increased their antimicrobial efficacy, especially in the case of streptomycin and tetracycline. Furthermore, the in vitro activity of the AgNPs on human cancer cell lines (MCF-7, A375, A549, and HepG2) showed cancer-specific sensitivity, while the genotoxic activity was evaluated by Ames assay, which revealed a lack of mutagenicity on the part of nanoparticles in Salmonella Typhimurium TA98 strain. We also studied the impact of the AgNPs on the catalytic and photocatalytic degradation of methyl orange (MO). The decomposition of MO was observed by a decrease in intensity of absorbance within time. The results of our study proved the easy, fast, and efficient synthesis of AgNPs using acidophilic actinomycete SL19 strain and demonstrated the remarkable potential of these AgNPs as anticancer and antibacterial agents. However, the properties and activity of such particles can vary by biosynthesized batch.
- Published
- 2022
- Full Text
- View/download PDF
30. Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism.
- Author
-
Koczurkiewicz-Adamczyk P, Gąsiorkiewicz B, Piska K, Gunia-Krzyżak A, Jamrozik M, Bucki A, Słoczyńska K, Bojdo P, Wójcik-Pszczoła K, Władyka B, Kołaczkowski M, and Pękala E
- Subjects
- Alcohol Oxidoreductases, Animals, Antibiotics, Antineoplastic metabolism, Antibiotics, Antineoplastic toxicity, Cardiotoxicity metabolism, Cardiotoxicity prevention & control, Cinnamates, Doxorubicin toxicity, Humans, Rats, Myocytes, Cardiac metabolism, Neoplasms metabolism
- Abstract
Doxorubicin (DOX) is classified by World Health Organization (WHO) as an essential medicine for cancer. However, its clinical application is limited due to resistance development and cardiotoxicity. Many attempts have been made to address these issues with some focused on finding a potential adjuvant therapy. Recently, inhibition of carbonyl reduction of anthracyclines (ANTs), catalyzed by enzymes from carbonyl reductase (CBR) and aldo-keto reductase (AKR) families, emerged as a potential way to simultaneously bypass cancer resistance and alleviate cardiotoxicity of ANTs. In this context, we evaluated the potential application of l synthetic cinnamic acid derivatives (CA) - 1a (2E)-3-(4- chlorophenyl)-1-(4-hydroxypiperidin-1-yl)prop-2-en-1 and 1b (2E)-1-(4-hydroxypiperidin-1-yl)-3-(2-methylphenyl)prop-2-en-1-one. The tested compounds were found to chemosensitize A549 human lung cancer cell line towards DOX-induced viability reduction and apoptosis, while having no effect in non-cancerous lung fibroblasts. Co-treatment with DOX + 1a/1b significantly inhibited the migration of A549 in a Transwell assay. The addition of 1a/1b alleviated menadione-induced viability reduction in H9c2 rat cardiomyoblast cell line. Accordingly, 1a/1b reduced DOX-induced reactive oxygen species (ROS) generation and increased glutathione levels. The compounds were also found to moderate autophagy process and limit inflammatory response in RAW 264.7 macrophage cell line. Inhibitory properties of the compounds towards CBR1 were simulated by molecular modeling and confirmed in vitro in enzyme inhibition assay with recombinant CBR1 protein. In contrast to 1b, 1a has strong CBR1 inhibition, which correlates well with more profound effect elicited by 1a uniformly throughout the other experiments. Finally, no mutagenic, genotoxic or hepatotoxic activity of the compounds were found. The possible products of cytochrome P450 mediated metabolism of 1a and 1b were also established to evaluate the potential impact of first pass effect. Our results suggest that 1a and 1b are promising candidates for DOX adjuvant therapy that may simultaneously chemosensitize cancer cells and alleviate cardiotoxicity. The higher activity of 1a may be linked with CBR1 inhibition., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
31. Pan-Phosphodiesterase Inhibitors Attenuate TGF-β-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation.
- Author
-
Wójcik-Pszczoła K, Chłoń-Rzepa G, Jankowska A, Ferreira B, Koczurkiewicz-Adamczyk P, Pękala E, Wyska E, Pociecha K, and Gosens R
- Abstract
Airway remodeling is a pathological process that accompanies many chronic lung diseases. One of the important players in this process are epithelial cells, which under the influence of pro-inflammatory and pro-fibrotic factors present in the airway niche, actively participate in the remodeling process by increasing extracellular matrix secretion, acquiring migration properties, and overproducing pro-fibrotic transducers. Here, we investigated the effect of three new 8-arylalkylamino- and 8-alkoxy-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7 H -purin-7-yl- N -(5-( tert -butyl)-2-hydroxyphenyl)butanamides ( 1 , 2 , and 3 ), representing prominent pan-phosphodiesterase (pan-PDE) inhibitors on transforming growth factor type β (TGF-β)-induced alveolar epithelial type II cells (A549 cell line) of a pro-fibrotic phenotype. Our results demonstrate for the first time the strong activity of pan-PDE inhibitors in the prevention of TGF-β-induced mesenchymal markers' expression and A549 cells' migration. We also showed an increased p-CREB and decreased p-Smad-2 phosphorylation in TGF-β-induced A549 cells treated with 1 , 2 , and 3 derivatives, thereby confirming a pan-PDE inhibitor mesenchymal phenotype reducing effect in alveolar epithelial type II cells via suppression of the canonical Smad signaling pathway. Our observations confirmed that PDE inhibitors, and especially those active against various isoforms involved in the airway remodeling, constitute an interesting group of compounds modulating the pro-fibrotic response of epithelial cells.
- Published
- 2022
- Full Text
- View/download PDF
32. Evaluation of Two Novel Hydantoin Derivatives Using Reconstructed Human Skin Model Episkin TM : Perspectives for Application as Potential Sunscreen Agents.
- Author
-
Słoczyńska K, Popiół J, Gunia-Krzyżak A, Koczurkiewicz-Adamczyk P, Żmudzki P, and Pękala E
- Subjects
- Humans, Permeability, Skin metabolism, Skin Irritancy Tests, Hydantoins pharmacology, Sunscreening Agents metabolism, Sunscreening Agents pharmacology
- Abstract
This study aimed to assess two novel 5-arylideneimidazolidine-2,4-dione (hydantoin) derivatives (JH3 and JH10) demonstrating photoprotective activity using the reconstructed human skin model Episkin
TM . The skin permeability, irritation, and phototoxicity of the compounds was evaluated in vitro. Moreover, the in vitro genotoxicity and human metabolism of both compounds was studied. For skin permeation and irritation experiments, the test compounds were incorporated into a formulation. It was shown that JH3 and JH10 display no skin irritation and no phototoxicity. Both compounds did not markedly enhance the frequency of micronuclei in CHO-K1 cells in the micronucleus assay. Preliminary in vitro studies with liver microsomes demonstrated that hydrolysis appears to constitute their important metabolic pathway. EpiskinTM permeability experiments showed that JH3 permeability was lower than or close to currently used UV filters, whereas JH10 had the potential to permeate the skin. Therefore, a restriction of this compound permeability should be obtained by choosing the right vehicle or by optimizing it, which should be addressed in future studies.- Published
- 2022
- Full Text
- View/download PDF
33. Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents.
- Author
-
Wójcik-Pszczoła K, Jankowska A, Ślusarczyk M, Jakieła B, Plutecka H, Pociecha K, Świerczek A, Popiół J, Koczurkiewicz-Adamczyk P, Wyska E, Pękala E, Gosens R, and Chłoń-Rzepa G
- Subjects
- Animals, Anti-Asthmatic Agents chemical synthesis, Anti-Asthmatic Agents chemistry, Anti-Inflammatory Agents chemical synthesis, Anti-Inflammatory Agents chemistry, Antifibrotic Agents chemical synthesis, Antifibrotic Agents chemistry, Antioxidants chemical synthesis, Antioxidants chemistry, Humans, Mice, Phosphodiesterase Inhibitors chemical synthesis, Phosphodiesterase Inhibitors chemistry, RAW 264.7 Cells, Anti-Asthmatic Agents pharmacology, Anti-Inflammatory Agents pharmacology, Antifibrotic Agents pharmacology, Antioxidants pharmacology, Phosphodiesterase Inhibitors pharmacology
- Abstract
Phosphodiesterase (PDE) inhibitors are currently an extensively studied group of compounds that can bring many benefits in the treatment of various inflammatory and fibrotic diseases, including asthma. Herein, we describe a series of novel N'-phenyl- or N'-benzylbutanamide and N'-arylidenebutanehydrazide derivatives of 8-aminopurine-2,6-dione (27-43) and characterized them as prominent pan-PDE inhibitors. Most of the compounds exhibited antioxidant and anti-inflammatory activity in lipopolysaccharide (LPS)-induced murine macrophages RAW264.7. The most active compounds (32-35 and 38) were evaluated in human bronchial epithelial cells (HBECs) derived from asthmatics. To better map the bronchial microenvironment in asthma, HBECs after exposure to selected 8-aminopurine-2,6-dione derivatives were incubated in the presence of two proinflammatory and/or profibrotic factors: transforming growth factor type β (TGF-β) and interleukin 13 (IL-13). Compounds 32-35 and 38 significantly reduced both IL-13- and TGF-β-induced expression of proinflammatory and profibrotic mediators, respectively. Detailed analysis of their inhibition preferences for selected PDEs showed high affinity for isoenzymes important in the pathogenesis of asthma, including PDE1, PDE3, PDE4, PDE7, and PDE8. The presented data confirm that structural modifications within the 7 and 8 positions of the purine-2,6-dione core result in obtaining preferable pan-PDE inhibitors which in turn exert an excellent anti-inflammatory and anti-fibrotic effect in the bronchial epithelial cells derived from asthmatic patients. This dual-acting pan-PDE inhibitors constitute interesting and promising lead structures for further anti-asthmatic agent discovery., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Low‑sodium dietary approach in the management of resistant and refractory hypertension: preliminary results.
- Author
-
Handzlik G, Szymańska E, Pękala E, Kędzierski L, Strzałkowska D, and Duława J
- Subjects
- Antihypertensive Agents therapeutic use, Diet, Humans, Hypertension drug therapy, Sodium
- Published
- 2021
- Full Text
- View/download PDF
35. Neuropathic pain-alleviating activity of novel 5-HT 6 receptor inverse agonists derived from 2-aryl-1H-pyrrole-3-carboxamide.
- Author
-
Drop M, Jacquot F, Canale V, Chaumont-Dubel S, Walczak M, Satała G, Nosalska K, Mahoro GU, Słoczyńska K, Piska K, Lamoine S, Pękala E, Masurier N, Bojarski AJ, Pawłowski M, Martinez J, Subra G, Bantreil X, Lamaty F, Eschalier A, Marin P, Courteix C, and Zajdel P
- Subjects
- Animals, Cell Line, Dose-Response Relationship, Drug, Humans, Male, Molecular Structure, Pyrroles chemistry, Pyrroles metabolism, Rats, Rats, Wistar, Serotonin Antagonists chemistry, Serotonin Antagonists metabolism, Structure-Activity Relationship, Neuralgia drug therapy, Pyrroles pharmacology, Receptors, Serotonin metabolism, Serotonin Antagonists pharmacology
- Abstract
The diverse signaling pathways engaged by serotonin type 6 receptor (5-HT
6 R) together with its high constitutive activity suggests different types of pharmacological interventions for the treatment of CNS disorders. Non-physiological activation of mTOR kinase by constitutively active 5-HT6 R under neuropathic pain conditions focused our attention on the possible repurposing of 5-HT6 R inverse agonists as a strategy to treat painful symptoms associated with neuropathies of different etiologies. Herein, we report the identification of compound 33 derived from the library of 2-aryl-1H-pyrrole-3-carboxamides as a potential analgesic agent. Compound 33 behaves as a potent 5-HT6 R inverse agonist at Gs, Cdk5, and mTOR signaling. Preliminary ADME/Tox studies revealed preferential distribution of 33 to the CNS and placed it in the low-risk safety space. Finally, compound 33 dose-dependently reduced tactile allodynia in spinal nerve ligation (SNL)-induced neuropathic rats., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
36. Multidirectional anti-melanoma effect of galactolipids (MGDG-1 and DGDG-1) from Impatiens parviflora DC. and their synergy with doxorubicin.
- Author
-
Grabowska K, Galanty A, Koczurkiewicz-Adamczyk P, Wróbel-Biedrawa D, Żmudzki P, Załuski D, Wójcik-Pszczoła K, Paśko P, Pękala E, and Podolak I
- Subjects
- Antineoplastic Agents chemistry, Biphenyl Compounds chemistry, Cell Line, Tumor, Cell Survival drug effects, Drug Synergism, Glycolipids chemistry, Humans, Impatiens, Monophenol Monooxygenase antagonists & inhibitors, Mutagenicity Tests, Picrates chemistry, Vibrio drug effects, Vibrio genetics, Antineoplastic Agents pharmacology, Doxorubicin pharmacology, Glycolipids pharmacology, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
The anti-melanoma potential of galactolipids: MGDG-1 and DGDG-1, isolated from Impatiens parviflora, and their synergistic effect with anticancer drug - doxorubicin (DOX) was investigated. Both compounds demonstrated time- and dose-dependent cytotoxicity against human melanoma cells of different metastatic potential. MGDG-1 was more effective than DGDG-1, with the highest activity against A375 cell line (IC
50 = 15.14 μg/mL). Both compounds acted selectively, were devoid of hepatotoxicity or mutagenicity. Additionally, MGDG-1 proved to be a tyrosinase inhibitor. Co-administration of MGDG-1 and DGDG-1 with DOX revealed a synergistic cytotoxic effect on melanoma cells. The cytotoxicity of all tested MGDG-1/DOX and DGDG-1/DOX cocktails was considerably higher than that of each agent administered alone. MGDG-1/DOX (Mix3) reduced the viability of A375 melanoma cells almost totally and this effect was 2-fold more potent as compared to DOX alone. Our study indicates that the overall effect is enhanced with the increasing concentration of MGDG-1 in the cocktail. These results open up a possibility for lowering therapeutic doses of chemotherapeutics such as doxorubicin when co-administrated with galactolipids. Thus, MGDG-1 can be prospectively considered as multidirectional anti-melanoma agent and can be recommended for further in vitro and in vivo studies, especially in search for effective combined therapy., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
37. A Comparative Survey of Anti-Melanoma and Anti-Inflammatory Potential of Usnic Acid Enantiomers-A Comprehensive In Vitro Approach.
- Author
-
Galanty A, Zagrodzki P, Gdula-Argasińska J, Grabowska K, Koczurkiewicz-Adamczyk P, Wróbel-Biedrawa D, Podolak I, Pękala E, and Paśko P
- Abstract
Usnic acid (UA) is a chiral lichen metabolite with an interesting pharmacological profile. The aim of this study was to compare the anti-melanoma effect of (+)-UA and (-)-UA in an in vitro model by studying their impact on the cells as well as the processes associated with cancer progression. The effect of UA enantiomers on the viability, proliferation, and invasive potential of three melanoma cell lines (HTB140, A375, WM793) was evaluated. Their interaction with a chemotherapeutic drug-doxorubicin was assessed by isobolographic analysis. Anti-inflammatory and anti-tyrosinase properties of (+)-UA and (-)-UA were also examined. Both UA enantiomers dose- and time-dependently decreased the viability of all three melanoma cell lines. Their synergistic effect with doxorubicin was observed on A375 cells. (+)-Usnic acid at a sub-cytotoxic dose strongly inhibited melanoma cells migration. Both UA enantiomers decreased the release of pro-inflammatory mediators. The cytotoxic effect of (+)-UA and (-)-UA depends greatly on the melanoma cell type; however, the overall anti-melanoma potential is perspective. Our results indicate that the strategy of combining usnic acid enantiomers with cytostatic drugs may be an interesting option to consider in combating melanoma; however, further studies are required.
- Published
- 2021
- Full Text
- View/download PDF
38. (+)-Usnic Acid as a Promising Candidate for a Safe and Stable Topical Photoprotective Agent.
- Author
-
Galanty A, Popiół J, Paczkowska-Walendowska M, Studzińska-Sroka E, Paśko P, Cielecka-Piontek J, Pękala E, and Podolak I
- Subjects
- Acrylates chemistry, Fibroblasts drug effects, Fibroblasts radiation effects, Humans, Keratinocytes drug effects, Keratinocytes radiation effects, Melanocytes drug effects, Melanocytes radiation effects, Radiation-Protective Agents chemistry, Radiation-Protective Agents pharmacology, Skin drug effects, Ultraviolet Rays, Benzofurans chemistry, Benzofurans pharmacology
- Abstract
The study aimed to examine whether usnic acid-a lichen compound with UV-absorbing properties-can be considered as a prospective photoprotective agent in cosmetic products. Moreover, a comparison of two usnic acid enantiomers was performed to preselect the more effective compound. To meet this aim, an in vitro model was created, comprising the determination of skin-penetrating properties via skin-PAMPA assay, safety assessment to normal human skin cells (keratinocytes, melanocytes, fibroblasts), and examination of photostability and photoprotective properties. Both enantiomers revealed comparable good skin-penetrating properties. Left-handed usnic acid was slightly more toxic to keratinocytes (IC
50 80.82 and 40.12 µg/mL, after 48 and 72 h, respectively) than its right-handed counterpart. The latter enantiomer, in a cosmetic formulation, was characterized by good photoprotective properties and photostability, comparable to the UV filter octocrylene. Perhaps most interestingly, (+)-usnic acid combined with octocrylene in one formulation revealed enhanced photoprotection and photostability. Thus, the strategy can be considered for the potential use of (+)-usnic acid as a UV filter in cosmetic products. Moreover, the proposed model may be useful for the evaluation of candidates for UV filters.- Published
- 2021
- Full Text
- View/download PDF
39. Photodegradation of Bexarotene and Its Implication for Cytotoxicity.
- Author
-
Kryczyk-Poprawa A, Zupkó I, Bérdi P, Żmudzki P, Piotrowska J, Pękala E, Berdys A, Muszyńska B, and Opoka W
- Abstract
A detailed understanding of the stability of an active pharmaceutical ingredient and a pharmaceutical dosage form is essential for the drug-development process and for safe and effective use of medicines. Photostability testing as an inherent part of stability studies provides valuable knowledge on degradation pathways and structures of products generated under UV irradiation. Photostability is particularly important for topically administered drugs, as they are more exposed to UV radiation. Bexarotene is a more recent third-generation retinoid approved by the U.S. Food and Drug Administration and the European Medicines Agency as a topically applied anticancer agent. The present study aimed to assess bexarotene photostability, including the presence of UV filters, which have been permitted to be used in cosmetic products in Europe and the USA. The bexarotene photostability testing was performed in ethanol solutions and in formulations applied on PMMA plates. The UPLC-MS/MS technique was used to determine the tested substance. The presence of photocatalysts such as TiO
2 or ZnO, as well as the organic UV filters avobenzone, benzophenone-3, meradimate, and homosalate, could contribute to degradation of bexarotene under UV irradiation. Four photocatalytic degradation products of bexarotene were identified for the first time. The antiproliferative properties of the degradation products of bexarotene were assessed by MTT assay on a panel of human adherent cancer cells, and concentration-dependent growth inhibition was evidenced on all tested cell lines. The cytotoxicity of the formed products after 4 h of UV irradiation was significantly higher than that of the parent compound ( p < 0.05). Furthermore non-cancerous murine fibroblasts exhibited marked concentration-dependent inhibition by bexarotene, while the degradation products elicited more pronounced antiproliferative action only at the highest applied concentration.- Published
- 2021
- Full Text
- View/download PDF
40. Cinnamic Acid Derivatives as Cardioprotective Agents against Oxidative and Structural Damage Induced by Doxorubicin.
- Author
-
Koczurkiewicz-Adamczyk P, Klaś K, Gunia-Krzyżak A, Piska K, Andrysiak K, Stępniewski J, Lasota S, Wójcik-Pszczoła K, Dulak J, Madeja Z, and Pękala E
- Subjects
- Animals, Doxorubicin pharmacology, Hep G2 Cells, Humans, Rats, Cardiotonic Agents pharmacology, Cardiotoxicity drug therapy, Cardiotoxicity metabolism, Cardiotoxicity pathology, Cinnamates pharmacology, Doxorubicin adverse effects, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Oxidative Stress drug effects
- Abstract
Doxorubicin (DOX) is a widely used anticancer drug. However, its clinical use is severely limited due to drug-induced cumulative cardiotoxicity, which leads to progressive cardiomyocyte dysfunction and heart failure. Enormous efforts have been made to identify potential strategies to alleviate DOX-induced cardiotoxicity; however, to date, no universal and highly effective therapy has been introduced. Here we reported that cinnamic acid (CA) derivatives exert a multitarget protective effect against DOX-induced cardiotoxicity. The experiments were performed on rat cardiomyocytes (H9c2) and human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) as a well-established model for cardiac toxicity assessment. CA derivatives protected cardiomyocytes by ameliorating DOX-induced oxidative stress and viability reduction. Our data indicated that they attenuated the chemotherapeutic's toxicity by downregulating levels of caspase-3 and -7. Pre-incubation of cardiomyocytes with CA derivatives prevented DOX-induced motility inhibition in a wound-healing assay and limited cytoskeleton rearrangement. Detailed safety analyses-including hepatotoxicity, mutagenic potential, and interaction with the hERG channel-were performed for the most promising compounds. We concluded that CA derivatives show a multidirectional protective effect against DOX-induced cardiotoxicity. The results should encourage further research to elucidate the exact molecular mechanism of the compounds' activity. The lead structure of the analyzed CA derivatives may serve as a starting point for the development of novel therapeutics to support patients undergoing DOX therapy.
- Published
- 2021
- Full Text
- View/download PDF
41. Design, Synthesis and Biological Activity of New Amides Derived from 3-Benzhydryl and 3-sec-Butyl-2,5-dioxo-pyrrolidin-1-yl-acetic Acid.
- Author
-
Góra M, Czopek A, Rapacz A, Giza A, Koczurkiewicz-Adamczyk P, Pękala E, Obniska J, and Kamiński K
- Subjects
- Acetic Acid chemical synthesis, Acetic Acid chemistry, Amides chemical synthesis, Amides chemistry, Analgesics chemical synthesis, Analgesics chemistry, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Drug Design, Drug Screening Assays, Antitumor, Formaldehyde, Hep G2 Cells, Humans, Molecular Structure, Pain chemically induced, Seizures chemically induced, Structure-Activity Relationship, Acetic Acid pharmacology, Amides pharmacology, Analgesics pharmacology, Antineoplastic Agents pharmacology, Pain drug therapy, Seizures drug therapy
- Abstract
The aim of this study was to design and synthesize two new series of pyrrolidine-2,5-dione-acetamides with a benzhydryl or sec-butyl group at position 3 as potential anticonvulsants. Their anticonvulsant activity was evaluated in standard animal models of epilepsy: the maximal electroshock (MES), the 6 Hz, and the subcutaneous pentylenetetrazole (scPTZ) tests. The in vivo studies revealed the most potent anticonvulsant activity for 15 (3-(sec-butyl)-1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)-2-oxoethyl)pyrrolidine-2,5-dione), with ED
50 values of 80.38 mg/kg (MES) and 108.80 mg/kg (6 Hz). The plausible mechanism of action was assessed in in vitro binding assays, in which 15 interacted effectively with voltage-gated sodium (site 2) and L-type calcium channels at a concentration of 100 μM. Subsequently, the antinociceptive activity of compounds 7 and 15 was observed in the hot plate test of acute pain. Moreover, compounds 7, 11 and 15 demonstrated an analgesic effect in the formalin test of tonic pain. The hepatotoxic properties of the most effective compounds (7, 11 and 15) in HepG2 cells were also investigated., (© 2021 Wiley-VCH GmbH.)- Published
- 2021
- Full Text
- View/download PDF
42. Carbonyl reduction pathway in hepatic in vitro metabolism of anthracyclines: Impact of structure on biotransformation rate.
- Author
-
Piska K, Jamrozik M, Koczurkiewicz-Adamczyk P, Bucki A, Żmudzki P, Kołaczkowski M, and Pękala E
- Subjects
- Aclarubicin chemistry, Alcohol Oxidoreductases genetics, Alcohol Oxidoreductases metabolism, Aldo-Keto Reductase Family 1 Member C3 genetics, Aldo-Keto Reductase Family 1 Member C3 metabolism, Antineoplastic Agents chemistry, Antineoplastic Agents metabolism, Binding Sites, Biotransformation, Doxorubicin chemistry, Doxorubicin metabolism, Gene Expression Regulation, Enzymologic drug effects, Humans, Models, Molecular, Molecular Docking Simulation, Molecular Structure, Protein Conformation, Aclarubicin metabolism, Cytosol metabolism, Doxorubicin analogs & derivatives, Hepatocytes metabolism, Oxidoreductases metabolism
- Abstract
Carbonyl reduction biotransformation pathway of anthracyclines (doxorubicin, daunorubicin) is a significant process, associated with drug metabolism and elimination. However, it also plays a pivotal role in anthracyclines-induced cardiotoxicity and cancer resistance. Herein, carbonyl reduction of eight anthracyclines, at in vivo relevant concentrations (20 μM), was studied in human liver cytosol, to describe the relationship between their structure and metabolism. Significant differences of intrinsic clearance between anthracyclines, ranging from 0,62-74,9 μL/min/mg were found and associated with data from in silico analyses, considering their binding in active sites of the main anthracyclines-reducing enzymes: carbonyl reductase 1 (CBR1) and aldo-keto reductase 1C3 (AKR1C3). Partial atomic charges of carbonyl oxygen atom were also determined and considered as a factor associated with reaction rate. Structural features, including presence or absence of side-chain hydroxy group, a configuration of sugar chain hydroxy group, and tetracyclic rings substitution, affecting anthracyclines susceptibility for carbonyl reduction were identified., Competing Interests: Declaration of Competing Interest The authors report no declarations of interest., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
43. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer.
- Author
-
Gąsiorkiewicz BM, Koczurkiewicz-Adamczyk P, Piska K, and Pękala E
- Subjects
- Antineoplastic Agents therapeutic use, Autophagic Cell Death drug effects, Autophagic Cell Death physiology, Cell Survival physiology, Epigenesis, Genetic physiology, Humans, Lysosomes drug effects, Lysosomes physiology, Neoplasms drug therapy, Antineoplastic Agents pharmacology, Autophagy drug effects, Autophagy physiology, Cisplatin pharmacology, Drug Resistance, Neoplasm drug effects
- Abstract
Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic efficacy. Autophagy modulation has become an important area of interest regarding the aforementioned topic. Autophagy is a highly conservative cellular self-digestive process implicated in response to multiple environmental stressors. The high basal level of autophagy is a common phenomenon in cisplatin-resistant cancer cells which is thought to grant survival benefit. However current evidence supports the role of autophagy in either promoting or limiting carcinogenesis depending on the context. This encourages the search of substances modulating the process to alleviate cisplatin resistance. Such a strategy encompasses not only simple autophagy inhibition but also harnessing the process to induce autophagy-dependent cell death. In this paper, we briefly describe the mechanism of cisplatin resistance with a special emphasis on autophagy and we give an extensive literature review of potential substances with cisplatin chemosensitising properties related to autophagy modulation.
- Published
- 2021
- Full Text
- View/download PDF
44. Synthesis, Anticonvulsant, and Antinociceptive Activity of New 3-(2-Chlorophenyl)- and 3-(3-Chlorophenyl)-2,5-dioxo-pyrrolidin-1-yl-acetamides.
- Author
-
Góra M, Czopek A, Rapacz A, Gębska A, Wójcik-Pszczoła K, Pękala E, and Kamiński K
- Subjects
- Analgesics chemistry, Animals, Anticonvulsants chemistry, Cell Line, Disease Models, Animal, Drug Evaluation, Preclinical, Hep G2 Cells, Humans, In Vitro Techniques, Male, Mice, Molecular Structure, Neuralgia drug therapy, Pyrrolidines chemistry, Seizures drug therapy, Structure-Activity Relationship, Analgesics chemical synthesis, Analgesics pharmacology, Anticonvulsants chemical synthesis, Anticonvulsants pharmacology, Pyrrolidines chemical synthesis, Pyrrolidines pharmacology
- Abstract
The new series of 3-(2-chlorophenyl)- and 3-(3-chlorophenyl)-pyrrolidine-2,5-dione-acetamide derivatives as potential anticonvulsant and analgesic agents was synthesized. The compounds obtained were evaluated in the following acute models of epilepsy: maximal electroshock (MES), psychomotor (6 Hz, 32 mA), and subcutaneous pentylenetetrazole ( sc PTZ) seizure tests. The most active substance-3-(2-chlorophenyl)-1-{2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxoethyl}-pyrrolidine-2,5-dione ( 6 ) showed more beneficial ED
50 and protective index values than the reference drug-valproic acid (68.30 mg/kg vs. 252.74 mg/kg in the MES test and 28.20 mg/kg vs. 130.64 mg/kg in the 6 Hz (32 mA) test, respectively). Since anticonvulsant drugs are often effective in neuropathic pain management, the antinociceptive activity for two the promising compounds-namely, 6 and 19 -was also investigated in the formalin model of tonic pain. Additionally, for the aforementioned compounds, the affinity for the voltage-gated sodium and calcium channels, as well as GABAA and TRPV1 receptors, was determined. As a result, the most probable molecular mechanism of action for the most active compound 6 relies on interaction with neuronal voltage-sensitive sodium (site 2) and L-type calcium channels. Compounds 6 and 19 were also tested for their neurotoxic and hepatotoxic properties and showed no significant cytotoxic effect.- Published
- 2021
- Full Text
- View/download PDF
45. Imidazopyridine-Based 5-HT 6 Receptor Neutral Antagonists: Impact of N 1 -Benzyl and N 1 -Phenylsulfonyl Fragments on Different Receptor Conformational States.
- Author
-
Vanda D, Canale V, Chaumont-Dubel S, Kurczab R, Satała G, Koczurkiewicz-Adamczyk P, Krawczyk M, Pietruś W, Blicharz K, Pękala E, Bojarski AJ, Popik P, Marin P, Soural M, and Zajdel P
- Subjects
- Animals, Astrocytes drug effects, Humans, Learning Disabilities chemically induced, Learning Disabilities prevention & control, Male, Molecular Conformation, Neurites drug effects, Neuroglia drug effects, Neuroprotective Agents chemical synthesis, Neuroprotective Agents pharmacology, Rats, Rats, Sprague-Dawley, Receptors, G-Protein-Coupled drug effects, Serotonin Receptor Agonists pharmacology, Structure-Activity Relationship, Imidazoles chemical synthesis, Imidazoles pharmacology, Pyridines chemical synthesis, Pyridines pharmacology, Receptors, Serotonin drug effects, Serotonin Antagonists chemical synthesis, Serotonin Antagonists pharmacology
- Abstract
G-protein coupled receptors (GPCRs) exist in an equilibrium of multiple conformational states, including different active states, which depend on the nature of the bound ligand. In consequence, different conformational states can initiate specific signal transduction pathways. The study identified compound 7e , which acts as a potent 5-hydroxytryptamine type 6 receptor (5-HT
6 R) neutral antagonist at Gs and does not impact neurite growth (process controlled by Cdk5). MD simulations highlighted receptor conformational changes for 7e and inverse agonist PZ-1444. In cell-based assays, neutral antagonists of the 5-HT6 R ( 7e and CPPQ), but not inverse agonists (SB-258585, intepirdine, PZ-1444), displayed glioprotective properties against 6-hydroxydopamine-induced and doxorubicin-induced cytotoxicity. These suggest that targeting the activated conformational state of the 5-HT6 R with neutral antagonists implicates the protecting properties of astrocytes. Additionally, 7e prevented scopolamine-induced learning deficits in the novel object recognition test in rats. We propose 7e as a probe for further understanding of the functional outcomes of different states of the 5-HT6 R.- Published
- 2021
- Full Text
- View/download PDF
46. The Involvement of Xanthone and ( E )-Cinnamoyl Chromophores for the Design and Synthesis of Novel Sunscreening Agents.
- Author
-
Popiół J, Gunia-Krzyżak A, Słoczyńska K, Koczurkiewicz-Adamczyk P, Piska K, Wójcik-Pszczoła K, Żelaszczyk D, Krupa A, Żmudzki P, Marona H, and Pękala E
- Subjects
- Humans, Molecular Structure, Mutagenicity Tests, Skin drug effects, Skin radiation effects, Skin Aging drug effects, Skin Aging radiation effects, Spectrophotometry, Ultraviolet, Structure-Activity Relationship, Sunburn prevention & control, Sunscreening Agents chemical synthesis, Sunscreening Agents pharmacology, Xanthones pharmacology, Cinnamomum zeylanicum chemistry, Sunscreening Agents chemistry, Ultraviolet Rays, Xanthones chemistry
- Abstract
Excessive UV exposure contributes to several pathological conditions like skin burns, erythema, premature skin aging, photodermatoses, immunosuppression, and skin carcinogenesis. Effective protection from UV radiation may be achieved with the use of sunscreens containing UV filters. Currently used UV filters are characterized by some limitations including systemic absorption, endocrine disruption, skin allergy induction, and cytotoxicity. In the research centers all over the world new molecules are developed to improve the safety, photostability, solubility, and absorption profile of new derivatives. In our study, we designed and synthesized seventeen novel molecules by combining in the structures two chromophores: xanthone and ( E )-cinnamoyl moiety. The ultraviolet spectroscopic properties of the tested compounds were confirmed in chloroform solutions. They acted as UVB or UVA/UVB absorbers. The most promising compound 9 (6-methoxy-9-oxo-9 H -xanthen-2-yl)methyl ( E )-3-(2,4-dimethoxyphenyl)acrylate) absorbed UV radiation in the range 290-369 nm. Its photoprotective activity and functional photostability were further evaluated after wet milling and incorporation in the cream base. This tested formulation with compound 9 possessed very beneficial UV protection parameters (SPF
in vitro of 19.69 ± 0.46 and UVA PF of 12.64 ± 0.32) which were similar as broad-spectrum UV filter tris-biphenyl triazine. Additionally, compound 9 was characterized by high values of critical wavelength (381 nm) and UVA/UVB ratio (0.830) thus it was a good candidate for broad-spectrum UV filter and it might protect skin against UVA-induced photoaging. Compound 9 were also shown to be photostable, non-cytotoxic at concentrations up to 50 µM when tested on five cell lines, and non-mutagenic in Ames test. It also possessed no estrogenic activity, according to the results of MCF-7 breast cancer model. Additionally, its favorable lipophilicity (miLogP = 5.62) does not predispose it to penetrate across the skin after topical application., Competing Interests: The authors declare no conflict of interest.- Published
- 2020
- Full Text
- View/download PDF
47. A dual-acting 5-HT 6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties.
- Author
-
Canale V, Grychowska K, Kurczab R, Ryng M, Keeri AR, Satała G, Olejarz-Maciej A, Koczurkiewicz P, Drop M, Blicharz K, Piska K, Pękala E, Janiszewska P, Krawczyk M, Walczak M, Chaumont-Dubel S, Bojarski AJ, Marin P, Popik P, and Zajdel P
- Subjects
- Alkynes chemical synthesis, Alkynes pharmacokinetics, Animals, Astrocytes drug effects, Cell Line, Tumor, Drug Inverse Agonism, HEK293 Cells, Humans, Indoles chemical synthesis, Indoles pharmacokinetics, Male, Molecular Structure, Monoamine Oxidase Inhibitors chemical synthesis, Monoamine Oxidase Inhibitors pharmacokinetics, Neuroprotective Agents chemical synthesis, Neuroprotective Agents pharmacokinetics, Nootropic Agents chemical synthesis, Nootropic Agents pharmacokinetics, Rats, Sprague-Dawley, Rats, Wistar, Serotonin Antagonists chemical synthesis, Serotonin Antagonists pharmacokinetics, Serotonin Antagonists pharmacology, Structure-Activity Relationship, Alkynes pharmacology, Indoles pharmacology, Monoamine Oxidase Inhibitors pharmacology, Neuroprotective Agents pharmacology, Nootropic Agents pharmacology, Receptors, Serotonin metabolism
- Abstract
The complex etiology of Alzheimer's disease has initiated a quest for multi-target ligands to address the multifactorial causes of this neurodegenerative disorder. In this context, we designed dual-acting 5-HT
6 receptor (5-HT6 R) antagonists/MAO-B inhibitors using pharmacophore hybridization strategy. Our approach involved linking priviliged scaffolds of 5-HT6 R with aryloxy fragments derived from reversible and irreversible MAO-B inhibitors. The study identified compound 48 that acts as an inverse agonist of 5-HT6 R at Gs signaling and an irreversible MAO-B inhibitor. Compound 48 showed moderate metabolic stability in rat microsomal assay, artificial membrane permeability, no hepatotoxicity, and it was well distributed to the brain. Additionally, 48 showed glioprotective properties in a model of cultured astrocytes using 6-OHDA as the cytotoxic agent. Finally, compound 48 (MED = 1 mg/kg, p.o.) fully reversed memory deficits in the NOR task induced by scopolamine in rats. A better understanding of effects exerted by dual-acting 5-HT6 R/MAO-B modulators may impact the future development of neurodegenerative-directed treatment strategies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
48. Medicinal potential of mycelium and fruiting bodies of an arboreal mushroom Fomitopsis officinalis in therapy of lifestyle diseases.
- Author
-
Fijałkowska A, Muszyńska B, Sułkowska-Ziaja K, Kała K, Pawlik A, Stefaniuk D, Matuszewska A, Piska K, Pękala E, Kaczmarczyk P, Piętka J, and Jaszek M
- Subjects
- Cell Proliferation, Humans, Neoplasms pathology, Tumor Cells, Cultured, Antioxidants pharmacology, Coriolaceae chemistry, Fruiting Bodies, Fungal cytology, Mycelium chemistry, Neoplasms drug therapy, Phenols analysis
- Abstract
Fomitopsis officinalis is a medicinal mushroom used in traditional European eighteenth and nineteenth century folk medicine. Fruiting bodies of F. officinalis were collected from the natural environment of Świętokrzyskie Province with the consent of the General Director for Environmental Protection in Warsaw. Mycelial cultures were obtained from fragments of F. officinalis fruiting bodies. The taxonomic position of the mushroom mycelium was confirmed using the PCR method. The presence of organic compounds was determined by HPLC-DAD analysis. Bioelements were determined by AF-AAS. The biochemical composition of the tested mushroom material was confirmed with the FTIR method. Antioxidant properties were determined using the DPPH method, and the antiproliferative activity was assessed with the use of the MTT test. The presence of indole compounds (L-tryptophan, 6-methyl-D,L-tryptophan, melatonin, 5-hydroxy-L-tryptophan), phenolic compounds (p-hydroxybenzoic acid, gallic acid, catechin, phenylalanine), and sterols (ergosterol, ergosterol peroxide) as well as trace elements was confirmed in the mycelium and fruiting bodies of F. officinalis. Importantly, a high level of 5-hydroxy-L-tryptophan in in vitro mycelium cultures (517.99 mg/100 g d.w) was recorded for the first time. The tested mushroom extracts also showed antioxidant and antiproliferative effects on the A549 lung cancer cell line, the DU145 prostate cancer cell line, and the A375 melanoma cell line.
- Published
- 2020
- Full Text
- View/download PDF
49. Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells - Involvement of carbonyl reductase 1.
- Author
-
Koczurkiewicz-Adamczyk P, Piska K, Gunia-Krzyżak A, Bucki A, Jamrozik M, Lorenc E, Ryszawy D, Wójcik-Pszczoła K, Michalik M, Marona H, Kołaczkowski M, and Pękala E
- Subjects
- Doxorubicin, Humans, Carbonyl Reductase (NADPH), Cinnamates pharmacology, Lung Neoplasms drug therapy
- Abstract
Doxorubicin (DOX) therapy is limited by both cancer cells resistance and cardiotoxicity. DOX biotransformation to doxorubicinol (DOXol) by reductases enzymes (mainly by CBR1; carbonyl reductase 1) is a key process responsible for DOX adverse effects development. Thus, inhibition of CBR1 can increase the therapeutic effect of DOX. In the present study, we used a group of new synthetized cinnamic acid (CA) derivatives to improve the effectiveness and safety profile of DOX therapy against cancer cells in vitro. The possible mechanism of CBR1 inhibition was simulated by molecular modelling studies. The kinetics of DOX reduction in the presence of active CA derivatives were measured in cytosols. The chemosensitising activity of CA derivatives including proapoptotic, anti-invasiveness activity were investigated in A549 lung cancer cell line. In our research 7 from 16 tested CA derivatives binded to the active site of CBR1 enzyme and improved DOX stability by inhibition of DOXol formation. Co-treatment of A549 cells with active CA derivatives and DOX induced cells apoptosis by activation of caspase cascade. At the same time we observed decrease of invasive properties (cell migration and transmigration assays) and the rearangments of F-actin cytoskeleton in CA derivatves + DOX treated cells. Meanwhile, control, human lung fibroblasts stay realtivelly unvulnerable and viable. New synthetized CA derivatives may inhibit the activity of CBR1 leading to the stabilization of DOX therapeutic levels in cancer cells and to protect the myocardium against DOXol cytotoxic effect. Favourable physicochemical properties supported by a safety profile and multidirectional chemosensitising activity render CA derivatives a promising group for the development of agent useful in combined therapy., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
50. Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives.
- Author
-
Czopek A, Partyka A, Bucki A, Pawłowski M, Kołaczkowski M, Siwek A, Głuch-Lutwin M, Koczurkiewicz P, Pękala E, Jaromin A, Tyliszczak B, Wesołowska A, and Zagórska A
- Subjects
- Animals, Behavior, Animal drug effects, Disease Models, Animal, Hep G2 Cells, Humans, Mice, Phosphoric Diester Hydrolases metabolism, Receptor, Serotonin, 5-HT1A metabolism, Receptors, Serotonin metabolism, Schizophrenia drug therapy, Structure-Activity Relationship, Antipsychotic Agents chemical synthesis, Antipsychotic Agents chemistry, Antipsychotic Agents pharmacology, Molecular Docking Simulation, Phosphoric Diester Hydrolases chemistry, Receptor, Serotonin, 5-HT1A chemistry, Receptors, Serotonin chemistry
- Abstract
In this study, a series of compounds derived from 4-methoxy-1 H -isoindole-1,3(2 H )-dione, potential ligands of phosphodiesterase 10A and serotonin receptors, were investigated as potential antipsychotics. A library of 4-methoxy-1 H -isoindole-1,3(2 H )-dione derivatives with various amine moieties was synthesized and examined for their phosphodiesterase 10A (PDE10A)-inhibiting properties and their 5-HT
1A and 5-HT7 receptor affinities. Based on in vitro studies, the most potent compound, 18 (2-[4-(1 H -benzimidazol-2-yl)butyl]-4-methoxy-1 H -isoindole-1,3(2 H )-dione), was selected and its safety in vitro was evaluated. In order to explain the binding mode of compound 18 in the active site of the PDE10A enzyme and describe the molecular interactions responsible for its inhibition, computer-aided docking studies were performed. The potential antipsychotic properties of compound 18 in a behavioral model of schizophrenia were also investigated.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.